8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 17, 2007

SALIX PHARMACEUTICALS, LTD.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

000-23265	94-3267443
(Commission File Number)	(IRS Employer ID Number)

1700 Perimeter Park Drive, Morrisville, North Carolina	27560
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code (919) 862-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On May 17, 2007 Salix Pharmaceuticals, Ltd. issued a press release announcing that results of 18 investigator-initiated trials related to the Company’s products will be presented at Digestive Disease Week^® 2007, which will be held May 19-24, 2007. A copy of this press release is attached hereto and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

Exhibit No.	Description
99.1	Press release dated May 17, 2007

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

	SALIX PHARMACEUTICALS, LTD.
Date: May 17, 2007
	/s/ Adam C. Derbyshire
	Adam C. Derbyshire
	Senior Vice President and Chief Financial Officer

EX-99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE

Contact:	Adam C. Derbyshire	Mike Freeman
	Senior Vice President and Chief Financial Officer	Executive Director, Investor Relations and Corporate Communications
	919-862-1000	919-862-1000

SALIX PHARMACEUTICALS PREVIEWS

DIGESTIVE DISEASE WEEK 2007

RALEIGH, NC, May 17, 2007—Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that results of 18 investigator-initiated trials related to the Company’s products will be presented at Digestive Disease Week^® 2007, which will be held May 19-24, 2007. Digestive Disease Week is considered the largest and most prestigious meeting in the world for the GI professional. Every year it attracts more than 16,000 physicians, researchers and academics from around the world who desire to stay up-to-date in their respective fields. The meeting is the year’s best opportunity to learn about the latest advances in gastroenterology, hepatology, endoscopy and gastrointestinal surgery; prevention, diagnosis and treatment of digestive disorders; and cutting-edge technological advances.

POSTER PRESENTATIONS:

TOPIC	LEAD AUTHOR	DATE
XIFAXAN
An open label series of rifaximin for long term maintenance therapy for patients with refractory pouchitis	A. Kornbluth, M.D.	May 20
History of hypothyroidism is associated to small intestinal bacterial overgrowth	E. Lauritano, M.D.	May 20
High dosage rifaximin for the treatment of small intestinal overgrowth	E. Scarpellini, M.D.	May 20

High recurrence of small intestinal bacterial overgrowth after antibiotic	E. Lauritano, M.D.	May 20
Rifaximin versus systemic antibiotics for the treatment of small bowel bacterial overgrowth	M. Gabrelli, M.D.	May 20
Small intestinal bacterial overgrowth in acromegalic patients	A. Parodi, M.D.	May 20
May breath test be useful in diagnosis of IBS patients? an Italian Study	A. Parodi, M.D.	May 20
The oral nonsystemic antibiotic rifaximin prevents symptom recurrence in patients with recurrent C. difficile-associated diarrhea	H. DuPont, M.D.	May 20
Characterization of C. difficile strain isolated from patients with hospital-associated diarrhea	Z. Jiang, M.D.	May 20
The effect of selective intestinal decontamination on liver hemodynamics in patients with alcohol related decompensated cirrhosis	A. Saveriadis, M.D.	May 20
Restless leg syndrome in patients with irritable bowel disease: response to bacterial overgrowth therapy	L. Weinstock, M.D.	May 21
Small intestinal bacterial overgrowth in patients with interstitial cystitis and gastrointestinal symptoms	L. Weinstock, M.D.	May 21
Double blind, randomized study to evaluate efficacy and urinary excretional rate of two doses of rifaximin-EIR in mild to moderate active Crohn’s disease (GRACE 02 study)	M. Lukas, M.D.	May 22
Rifaximin as a steroid-sparing medication in the management of patients with mild to moderate inflammatory bowel disease	T. Shah, M.D.	May 23
Decreasing rates of colectomy despite high rates of hospitalization in C. difficile infected IBD patients: a tertiary referral center experience	M. Issa, M.D.	May 23
MOVIPREP
Better efficacy of a new 2-liter bowel cleansing preparation in the ascending colon	L. Clark	May 22
Randomised and controlled clinical trial of polyethylene glycol with electrolytes and ascorbic acid in comparison to sodium phosphate for bowel preparation before colon cancer screening colonoscopy	H. Gruss	May 23

COLAZAL
Efficacy and safety of balsalazide for treatment of pediatric patients with mild to moderate ulcerative colitis: A randomized double-blind study	J. Quiros	May 22

CONTINUING MEDICAL EDUCATION ACTIVITIES

In addition, Salix is supporting, through an unrestricted educational grant, two continuing medical education activities in conjunction with DDW this year:

“Navigating the Clinical Maze of GI Disorders”

Faculty Chair

Gary Lichtenstein, M.D.

Professor of Medicine

Director, Center for Inflammatory Bowel Disease

University of Pennsylvania School of Medicine

“Maximizing Neoplasia Detection during Colonoscopy: Bowel Preparation Technique and Technology”

Faculty Chair

Douglas Rex, M.D.

Chancellor’s Professor

Indiana University – Purdue University

Professor of Medicine

Indiana University School of Medicine

Director of Endoscopy

Indiana University Hospital

DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases, the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract, DDW takes place May 19-24, 2007, at the

Washington Convention Center, Washington, DC. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. For more information, visit www.ddw.org.

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company’s gastroenterology specialty sales and marketing team.

COLAZAL^® (balsalazide disodium) Capsules 750 mg, is an anti-inflammatory drug approved for the treatment of mildly to moderately active ulcerative colitis. Safety and effectiveness of COLAZAL beyond 12 weeks has not been established. COLAZAL was well tolerated in clinical studies. In clinical trials, patients reported the following adverse events most frequently: headache (8%); abdominal pain (6%); diarrhea (5%); nausea (5%); vomiting (4%); respiratory infection (4%); and arthralgia (4%). Withdrawal from therapy due to adverse events was comparable to placebo.

XIFAXAN^® (rifaximin) tablets 200 mg are indicated for the treatment of patients (³12 years of age) with travelers’ diarrhea caused by noninvasive strains of Escherichia coli. XIFAXAN should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than Escherichia coli. XIFAXAN should be discontinued if diarrhea symptoms get worse or persist more than 24-48 hours and alternative antibiotic therapy should be considered. In clinical trials, XIFAXAN was generally well tolerated. The most common side effects (vs. placebo) were flatulence 11.3% (vs. 19.7%), headache 9.7% (vs. 9.2%), abdominal pain 7.2% (vs. 10.1 %) and rectal tenesmus 7.2% (vs. 8.8%).

MOVIPREP^® (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) is indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. MOVIPREP should be used with caution in patients using concomitant medications that increase the risk of electrolyte abnormalities such as diuretics or angiotensin converting enzyme (ACE)-inhibitors or in patients with known or suspected hyponatremia. MOVIPREP should also be used with caution in patients with severe ulcerative colitis, ileus, gastrointestinal obstruction or perforation, gastric retention, toxic colitis, or toxic megacolon. In clinical trials, abdominal distension, anal discomfort, thirst, nausea and abdominal pain were some of the most common adverse reactions to MOVIPREP administration. Vomiting occurred less frequently.

Salix also markets OSMOPREP™ Tablets (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP), VISICOL^® Tablets (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous), PEPCID^® (famotidine) Oral Suspension, DIURIL^® (chlorothiazide) Oral Suspension,AZASAN^® (Azathioprine Tablets, USP), ANUSOL-HC^® (Hydrocortisone Cream, USP) and PROCTOCORT^® (Hydrocortisone Cream, USP). Balsalazide disodium tablets, granulated mesalamine, SANVAR^® (600 ug vials vapreotide acetate powder) and Xifaxan are under development for additional indications.

Salix trades on the NASDAQ Market under the ticker symbol “SLXP.”

For more information please contact the Company at 919-862-1000 or visit our web site at www.salix.com. Information on our web site is not incorporated in our SEC filings.

Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include risks of regulatory review and clinical trials, competition, intellectual property risks, market acceptance for approved products, management of rapid growth and the need to acquire additional products. The reader is referred to the documents that the Company files from time to time with the Securities and Exchange Commission.